91桃色

Chronic inflammation is increasingly recognized as a key factor in the development and progression of various cancers. The relationship between inflammation and cancer is complex, with prolonged inflammatory responses contributing to the initiation, progression, and metastasis of tumors. While acute inflammation is a natural immune response to injury or infection, chronic inflammation can lead to the persistence of pro-inflammatory cytokines, immune cells, and other factors that create a microenvironment conducive to tumorigenesis. This article explores the mechanisms through which chronic inflammation contributes to cancer development and highlights potential therapeutic implications for targeting inflammation in cancer prevention and treatment [1].

Description

Chronic inflammation and tumorigenesis

Chronic inflammation is characterized by long-term, low-grade inflammation that persists in the absence of infection or injury. This condition can result from factors such as infections (e.g., Helicobacter pylori in gastric cancer), autoimmune diseases (e.g., inflammatory bowel disease and colorectal cancer), environmental exposures (e.g., smoking and lung cancer), and lifestyle factors (e.g., obesity and metabolic syndrome).

Inflammatory mediators in cancer

Chronic inflammation leads to the continuous release of inflammatory mediators, including cytokines, chemokines, prostaglandins, and reactive oxygen species (ROS), which create a tumor-promoting microenvironment [2]. Key cytokines like tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β are involved in activating various signaling pathways that promote cancer cell proliferation, survival, angiogenesis, and metastasis. For example, IL-6 activates the JAK/STAT pathway, promoting tumor growth and survival, while TNF-α can stimulate the NF-κB pathway, leading to an increase in tumor cell invasion and resistance to apoptosis.

Immune cell infiltration and tumor promotion

Chronic inflammation often involves the recruitment of immune cells, such as macrophages, neutrophils, and lymphocytes, to the site of inflammation. These cells, particularly tumor-associated macrophages (TAMs), play a dual role in cancer. While they are part of the body's defense mechanism, in the tumor microenvironment, they can adopt a pro-tumorigenic phenotype (M2 macrophages) [3]. These macrophages secrete factors like vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs), which promote angiogenesis and tissue remodeling, facilitating tumor growth and metastasis. Similarly, neutrophils and T-cells can release inflammatory mediators that further drive tumor progression.

DNA damage and genomic instability

Chronic inflammation contributes to DNA damage through the generation of ROS and reactive nitrogen species (RNS). These highly reactive molecules can cause mutations, deletions, and chromosomal instability, increasing the likelihood of cancerous transformation. Additionally, inflammatory mediators can influence DNA repair mechanisms, potentially leading to an accumulation of mutations over time. This genomic instability is a hallmark of many cancers and a critical step in tumorigenesis [4].

Inflammation and the tumor microenvironment

The tumor microenvironment (TME) is shaped by a variety of factors, including immune cells, extracellular matrix components, and signaling molecules. Chronic inflammation disrupts the TME, creating a favorable environment for tumor growth. Inflammatory mediators like cytokines and growth factors activate stromal cells, fibroblasts, and endothelial cells, which contribute to tumor vascularization, immune evasion, and metastasis. The inflammatory response also impairs normal tissue repair and immune surveillance, allowing cancer cells to thrive and spread [5].

Therapeutic implications

The strong connection between chronic inflammation and cancer has prompted significant interest in targeting inflammatory pathways as a therapeutic strategy in cancer prevention and treatment. Several approaches are being explored to modulate inflammation and reduce cancer risk.

Anti-inflammatory drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, have been studied for their potential to prevent cancer. NSAIDs inhibit cyclooxygenase-2 (COX-2), an enzyme involved in inflammation and tumorigenesis. Preclinical and clinical studies have shown that NSAIDs can reduce the risk of colorectal cancer and other cancers associated with chronic inflammation [6]. However, the long-term use of NSAIDs for cancer prevention remains controversial due to potential side effects, such as gastrointestinal bleeding.

Targeting inflammatory signaling pathways

A more targeted approach involves inhibiting specific inflammatory signaling pathways involved in cancer. For example, the NF-κB and JAK/STAT pathways are central to inflammation and tumorigenesis. Inhibitors of these pathways, such as proteasome inhibitors and JAK inhibitors, are being investigated for their potential to reduce inflammation and suppress tumor growth. These targeted therapies aim to block the pro-tumorigenic effects of inflammation without causing broad immune suppression [7].

Immunomodulation: Since the immune system plays a significant role in chronic inflammation and tumor progression, modulating immune responses is another promising strategy. Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies) have revolutionized cancer treatment by enhancing immune responses against tumors. However, these therapies also influence inflammation, and there is growing interest in understanding how to optimize their effectiveness in patients with chronic inflammation.

Diet and lifestyle modifications: Lifestyle factors such as diet, physical activity, and weight management can influence inflammation levels. A diet rich in anti-inflammatory foods (e.g., fruits, vegetables, and omega-3 fatty acids) may help modulate inflammation and reduce cancer risk [8]. Conversely, diets high in processed foods, red meat, and unhealthy fats may exacerbate inflammation and increase cancer susceptibility. Lifestyle interventions aimed at reducing obesity and promoting healthy habits could serve as preventative measures against inflammation-related cancers.

Targeting the tumor microenvironment: Strategies to normalize the TME by modulating immune cell infiltration and activity are also under investigation. For instance, reprogramming TAMs from a pro-tumorigenic M2 phenotype to an anti-tumorigenic M1 phenotype could reduce the inflammatory components that promote tumor growth and metastasis. Additionally, targeting angiogenesis and immune evasion mechanisms within the TME holds promise for reducing the cancer-promoting effects of chronic inflammation [9,10].

Conclusion

Chronic inflammation plays a critical role in tumorigenesis by creating a pro-tumorigenic microenvironment that supports cancer initiation, progression, and metastasis. The mechanisms underlying this process include the release of inflammatory mediators, immune cell infiltration, DNA damage, and disruption of the tumor microenvironment. Given the strong association between inflammation and cancer, targeting inflammatory pathways offers a promising avenue for cancer prevention and treatment. Ongoing research into anti-inflammatory drugs, immune modulation, and lifestyle interventions will help to identify effective strategies for reducing cancer risk and improving therapeutic outcomes. As our understanding of the complex relationship between inflammation and cancer deepens, new opportunities for innovative, inflammation-based cancer therapies will continue to emerge.

Acknowledgement

None

Conflict of Interest

None

1. Chen MJ, Shih SC, Wang HY, Lin CC, Liu CY, et al. (2013) . Evid-Based Complement Altern Med 270906.

, ,

2. Papademetrio DL, Lompard铆a SL, Simunovich T, Costantino S, Mihalez CY, et al. (2015) . Targ Oncol 1: 183-195.

, ,

3. Rzepecka-Stojko A, Kaba艂a-Dzik A, Mo藕dzierz A, Kubina R, Wojtyczka RD, et al. (2015) . Molecules 20: 9242-9262.

, ,

4. Omene C, Wu J, Frenkel K (2011) Invest New Drugs 30: 1279-1288.

, ,

5. Lonardo E, Hermann P, Heeschen C (2010) . Mol Oncol 4: 431-442.

, ,

6. Limptrakul P, Khantamat O, Pintha K (2005. J Chemoter 17: 86-95.

, ,

7. Lee J, Han S, Yun J, Kim J (2015) . Tumor Biol 36: 9385-9393.

, ,

8. Lu Qi, Zhang L, Yee J, Go VL, Lee W (2015) . Metabolomics 11: 71-80.

, ,

9. Bimonte S, Leongito M, Barbieri A, Vecchio V, Barbieri M, et al. (2015) . Infect Agents Cancer 10: 22.

, ,

10. Kostin S, McDonald D, McFadden D (2012) . J Surg Res 77: 255-262.

, ,